IDEAYA Biosciences, Inc. Total Contract Liability
IDEAYA Biosciences, Inc. (IDYA) had Total Contract Liability of $2.17 million as of 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2025-11-04
- 2025-09-30: Contract with Customer, Liability $2.17M.
- 2024-09-30: Contract with Customer, Liability $0.00.
- 2024-06-30: Contract with Customer, Liability $0.00.
- 2024-03-31: Contract with Customer, Liability $0.00.
| Period end | Contract with Customer, Liability | Contract with Customer, Liability as first filed |
|---|---|---|
| 2025-09-30 | $2.17M 10-Q · filed 2025-11-04 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-04 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $0.00 10-Q · filed 2024-11-04 | |
| 2023-09-30 | $1.44M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $2.82M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $6.25M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $13.75M 10-Q · filed 2023-11-07 | |
| 2022-09-30 | $17.58M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $43.87M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $49.44M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $60.23M 10-K · filed 2023-03-07 | |
| 2021-09-30 | $62.18M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $70.14M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | $77.57M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $83.77M 10-K · filed 2022-03-18 | $83.80M 10-K · filed 2021-03-23 |
| 2020-09-30 | $91.00M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |